← The Wire
TBPHNasdaq
Theravance Biopharma, Inc.
Pharmaceutical Preparations · CA · CIK 1583107
Theravance Biopharma develops and commercializes medicines, earning revenue from collaborations and licensing
red 8-K · 90d⚡ Elevated coverage
$858M
Market cap
$17.06
Last close
-3.2%
1D
+3.0%
5D
3.1M
Volume
Price · last 39 sessions+0.9%
May 4L $15.58 · H $17.63Jun 29
261
Total filings
Jun 29, 2026
Last filing
12/31
Fiscal year end
10-K10-KMar 23, 202610-K10-KMar 7, 202510-K10-KMar 1, 202410-K10-KMar 1, 202310-K10-KFeb 28, 202210-K10-KFeb 26, 202110-K10-KFeb 27, 202010-K10-KFeb 28, 201910-K10-KFeb 28, 201810-K10-KMar 1, 201710-K10-KMar 11, 2016
Insider Activity
In the 90 days to Mar 16, 2026: 1 sold $434K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 16, 2026 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sell | 15,534 | $14.00 | $217K |
| Mar 16, 2026 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sell | 7,767 | $13.92 | $108K |
| Mar 16, 2026 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sell | 7,766 | $13.92 | $108K |
| Dec 3, 2025 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sell | 15,534 | $18.75 | $291K |
| Dec 3, 2025 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sell | 7,767 | $18.75 | $146K |
| Dec 3, 2025 | Farnum RhondaSVP, COMM & MEDICAL AFFAIRS | Sell | 7,766 | $18.75 | $146K |
| Nov 26, 2025 | Broshy EranDirector | Sell | 15,501 | $20.00 | $310K |
| Nov 26, 2025 | Broshy EranDirector | Sell | 14,000 | $20.00 | $280K |
| Nov 11, 2025 | Broshy EranDirector | Sell | 29,500 | $18.50 | $546K |
| Nov 11, 2025 | Broshy EranDirector | Sell | 15,500 | $18.50 | $287K |
| Nov 11, 2025 | Broshy EranDirector | Sell | 15,500 | $17.00 | $264K |
| Nov 11, 2025 | Broshy EranDirector | Sell | 15,500 | $17.00 | $264K |
| Nov 11, 2025 | Broshy EranDirector | Sell | 14,000 | $18.50 | $259K |
| Nov 11, 2025 | Broshy EranDirector | Sell | 14,000 | $18.50 | $259K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
In the News
⚡ Elevated coverageCoverage (30d): 2 reputable articles · skews ▲ positive.
ReutersZymeworks expands beyond cancer with $929 million Theravance acquisition22h agoBarron'sZymeworks to Buy Theravance for Lung Disease Drug. Both Stocks Are Sliding.23h ago
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗
Similar companies
Comparable business profile · signals at a glance